Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Nov 27;2(3):118-124.
doi: 10.3390/ph2030118.

Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?

Salvatore Novo  1 , Giovanni Fazio  2 , Elena Raccuglia  2
Affiliations
Review

Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?

Salvatore Novo et al. Pharmaceuticals (Basel). .

Erratum in

Abstract

The renin-angiotensin-aldosterone system (RAAS) plays a dominant role in the pathophysiology of hypertension, diabetes mellitus, chronic kidney disease and chronic heart failure. Therefore, drugs that block key components of the RAAS such as ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs) have gained wide clinical use for these indications. Despite progress, the morbidity and mortality of patients treated with ACEI or ARBs remain high. Aliskiren (Tekturna, Rasilez) is the first orally active inhibitor of renin approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg. Aliskiren is effective either as monotherapy or in combination with drugs from the other major classes. In this review we analyze and review the information already gained with Aliskiren, raises questions regarding the advantages of DRIs as monotherapy compared to marketed ACEIs and ARBs, their potential added value in combination with other RAAS modulators and other still unproven benefits in relation to prorenin and renin receptor biology.

Keywords: ACE inhibitors; RAS system; aliskiren; angiotensin receptor blockers.

PubMed Disclaimer

References

    1. Sealey J.E., Laragh J.H. Aliskiren. New prospective. Am. J. Hypertens. 2007;20:587–597. - PubMed
    1. Riccioni G., Vitulano N., D'Orazio N., Bellocci F. Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension. Adv. Ther. 2009;26:700–710. - PubMed
    1. Vaidyanathan S., Jarugula V., Dieterich H.A., Howard D., Dole W.P. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin. Pharmacokinet. 2008;47:515–531. - PubMed
    1. Persson F., Rossing P., Reinhard H., Juhl T., Stehouwer C.D., Schalkwijk C., Danser A.J., Boomsma F., Frandsen E., Parving H.H. Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care. 2009 Epub ahead of print. - PMC - PubMed
    1. Düsing R., Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr.Med. Res. Opin. 2009 Epub ahead of print. - PubMed

LinkOut - more resources